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Introduction: Patients with rheumatoid arthritis (RA) have increased risk of cardiovascular (CV) events. We sought
to test the hypothesis that due to increased inflammation, CV disease and risk factors are associated with increased
risk of future RA development.
Methods: The population-based Nord-Trøndelag health surveys (HUNT) were conducted among the entire adult
population of Nord-Trøndelag, Norway. All inhabitants 20 years or older were invited, and information was collected
through comprehensive questionnaires, a clinical examination, and blood samples. In a cohort design, data from
HUNT2 (1995–1997, baseline) and HUNT3 (2006–2008, follow-up) were obtained to study participants with RA
(n = 786) or osteoarthritis (n = 3,586) at HUNT3 alone, in comparison with individuals without RA or osteoarthritis at
both times (n = 33,567).
Results: Female gender, age, smoking, body mass index, and history of previous CV disease were associated with
self-reported incident RA (previous CV disease: odds ratio 1.52 (95% confidence interval 1.11-2.07). The findings
regarding previous CV disease were confirmed in sensitivity analyses excluding participants with psoriasis (odds ratio
(OR) 1.70 (1.23-2.36)) or restricting the analysis to cases with a hospital diagnosis of RA (OR 1.90 (1.10-3.27)) or
carriers of the shared epitope (OR 1.76 (1.13-2.74)). History of previous CV disease was not associated with increased
risk of osteoarthritis (OR 1.04 (0.86-1.27)).
Conclusion: A history of previous CV disease was associated with increased risk of incident RA but not
osteoarthritis.Introduction
Rheumatoid arthritis (RA) is a systemic, inflammatory
autoimmune disorder that primarily involves the joints.
Despite treatment advances, RA patients continue to
have higher mortality and morbidity rates than the
general population, predominantly related to increased
atherosclerotic cardiovascular (CV) disease [1,2]. The
traditional CV risk factors include age, gender, family
history, smoking, diabetes, hypertension, dyslipidemia,
obesity and sedentary lifestyle. RA patients carry a* Correspondence: ranjeny.thomas@uq.edu.au
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unless otherwise stated.higher burden of some of these factors. The disease oc-
curs most commonly after 40 years of age and is associ-
ated with accelerated cellular ageing [3]. A history of
smoking is associated both with RA development and
severity [4-6]. Physical inactivity is common in patients
with RA and may increase co-morbidity due to obesity
or diabetes, leading to an increased risk of CV mortality
[7]. Some studies have also suggested that myocardial
disease without atherosclerosis is more prominent in RA
patients. For example, an echocardiography study dem-
onstrated that RA patients asymptomatic for CV disease
had ischemia more frequently than controls, but they
also had fewer significant angiographic coronary artery
stenoses [8]. Likewise, an autopsy study showed that RA
patients had diffuse myocardial fibrosis or non-specifictd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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after excluding individuals with other known causes [9].
Inflammation plays a central role in the pathogenesis
of atherosclerosis, and the increase in CV disease and
mortality in RA may partly be explained by inflamma-
tory factors associated with RA, even after adjustment
for traditional CV risk factors [10,11]. We and others
showed that atherosclerosis is increased both in patients
with established RA and at presentation in patients with
recent-onset RA, as determined by increased carotid in-
tima media thickness and plaque, and is associated with
their inflammatory burden [12,13]. The risk for myocar-
dial infarction (MI) and possible CV death is already in-
creased within approximately 5 years after diagnosis of
RA depending upon age and presence of CV risk factors,
resulting in a 10-year absolute risk comparable to non-
RA individuals who were 5 to 10 years older [14].
It has been demonstrated that inflammation pre-dates
the onset of RA [15]. These data suggest that an in-
creased risk of CV disease might also precede the onset
of RA. The Rochester Epidemiology Project study dem-
onstrated that RA patients were more likely to have been
hospitalized because of MI prior to RA diagnosis [16].
However, a previous longitudinal cohort study found no
difference in the rate of MI, congestive heart failure or
angina between pre-RA and control individuals [17].
We hypothesized that CV risk factors and events are
more prominent in persons with incident RA, and that
this augments the risk of future RA development by in-
creasing inflammation. The aim of the study was there-
fore to investigate the effects of CV risk factors and CV
events on the development of RA, using a population-
based cohort study design. As a control to study whether
any findings were specific to RA or related to arthritis in
general, a parallel investigation was performed in partici-
pants with and without osteoarthritis.
Methods
The study participants were from the Nord-Trøndelag
Health Study (HUNT) population-based health surveys
conducted in the county of Nord-Trøndelag in Norway.
The county is fairly representative for Norway as a whole,
with a stable and ethnically homogenous population (3%
non-Caucasians). All inhabitants 20 years or older were
invited, and information was collected through compre-
hensive questionnaires and a clinical examination. The
HUNT2 survey has previously been described in detail
[18]. The HUNT3 survey had a similar design. In total,
about 75,000 (70% of those invited) participated in
HUNT2 (1995 to 1997), 51,000 (54% of those invited) par-
ticipated in HUNT3 (2006 to 2008), and 37,071 partici-
pated in both HUNT2 and HUNT3. By design, the
participants were not seen during the years between inclu-
sion in HUNT2 and HUNT3.The study cohort consisted of all participants in both
HUNT2 and HUNT3 who answered whether they had a
diagnosis of RA or not (n = 36,493, that is, 98.4% of
37,071) and this number determined the study size. Inci-
dent cases of RA were identified, that is, participants
who reported a diagnosis of RA in HUNT3 but not in
HUNT2. We also identified the incident cases of osteo-
arthritis for comparison, based on the question: “Has a
doctor ever said that you have/have had any of these dis-
eases: degenerative joint disease (osteoarthritis)?” The
question also included the Norwegian colloquial term
for osteoarthritis. Each patient group was compared to
the remaining participants of the study cohort.
Participants of HUNT gave informed consent. Ap-
proval for the study was obtained from the Regional
Committee on Medical Research Ethics, Central Norway,
the Norwegian Data Safety Authorities and the Norwegian
Department of Health. Ethics approval was also obtained
by the Metro South Ethics Committee Brisbane. Permis-
sion was granted from the two primary hospitals in
Nord-Trøndelag, Levanger and Namsos hospitals, and the
nearest secondary referral hospital, Trondheim University
Hospital, to link the identified RA cases in our study to
the hospital diagnosis registries for verification of diag-
nosis. The registered diagnoses are used for billing and re-
imbursement from the national insurance scheme. We
searched for the ICD-9 code 714 and ICD-10 codes M05
and M06 with sub-codes. We did not have permission to
access to the patients’ case notes in order to check that the
current criteria for RA were correctly employed.
On enrolment in HUNT2 and HUNT3 the participants
completed a questionnaire incorporating information on
medical history, smoking habits and family history of CV
disease, defined as a parent, sibling or child with previous
MI or stroke. Information on the use of lipid-lowering
medications or non-steroid anti-inflammatory drugs was
not available. Anthropometric and clinical measures in-
cluded height, weight, waist and hip circumference, and
blood pressure. Non-fasting blood samples were drawn and
total cholesterol, low-density lipoprotein (LDL) cholesterol,
high density lipoprotein (HDL) cholesterol, triglycerides
and serum glucose were measured using an autoanalyzer
(Hitachi Biocore Systems, Thornhill, ON, Canada). Using
DNA isolated at HUNT Biobank, participants with self-
reported RA were genotyped for the Shared Epitope [19].
Samples were genotyped using the Illumina Immunochip
microarray chip, and HLA-DRB1 genotypes then determined
by imputation using the program HLA-IMP [20,21]. Auto-
antibodies (anti-citrullinated peptide antibodies or ACPA,
rheumatoid factor) and C-reactive protein were not mea-
sured in this survey, and classification into seropositive or
seronegative RA was not possible. Hypertension was defined
as systolic blood pressure ≥140 mmHg, diastolic blood pres-
sure ≥90 mmHg or use of medication. Hypercholesterolemia
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mass index (BMI) was calculated as weight/height2 (kg/m2).
Patients who reported using over-the-counter analgesics
daily for one month or more during the last year before
inclusion in HUNT2 were recorded as users of analgesics.
Previous CV disease was defined as a composite of angina,
MI or stroke. The relevant questions were; “Have you had
or do you have angina pectoris?” “Have you had a stroke/
brain hemorrhage?” and “Have you had a myocardial
infarction?” The question about angina also included a
Norwegian colloquial term for this diagnosis. The com-
posite variable was used for previous CV disease as num-
bers of cases were too low for analysis of individual
disease events. The level of missingness at baseline for
most key variables was <1%, with the exception of smok-
ing (12.8% missing data). Missingness for smoking was
evenly distributed among the subgroups of the study co-
hort. Non-complete cases were omitted from analysis.
Statistical methods
Data are presented as number (percentage), mean (stand-
ard deviation) or median (interquartile range), as appropri-
ate. The chi-square test and the Mann-Whitney U-test
were used for between-group comparisons of categorical
and continuous study parameters, respectively. Risk factors
associated with the development of RA and osteoarthritis
between HUNT2 and HUNT3 were identified using
multivariate logistic regression models. Linearity of logits
for continuous variables was checked by plotting.
P-values <0.05 were considered significant. Pearson’s cor-
relation coefficient R was calculated to evaluate linear
correlation.
Since this was a population-based survey and RA was
self-reported, we performed several sensitivity analyses to
support our main analysis. Because previous studies have
indicated that few women with RA surveyed in the com-
munity report their diagnosis accurately [22], we repeated
the analysis in several subgroups of the incident RA cases
using additional criteria to remove false-positive diag-
noses, that is, 1) excluding all who also reported having
psoriasis (n = 178), 2) including only patients where the
diagnostic registries of the nearest hospitals showed a
diagnosis of RA (n = 216), 3) restricting the hospital-
diagnosed cases to those where the diagnosis first oc-
curred after 1999 or 4) after 2001, to avoid including
patients who forgot to report RA in HUNT2, or 5) includ-
ing only incident RA cases who carried the shared epitope
(with and without additional exclusion due to a report of
psoriasis). To represent the CV risk factors in another
way, we developed alternative models including the
Framingham risk score, which is based on age, serum
cholesterol, hypertension, smoking and diabetes [23], as
well as gender and history of CV disease. The Framingham
risk score was preferred because it assigns higher risk withdiabetes and there are no age limits, and because it may
easily be calculated in large cohorts. The European Heart-
Score [24] is based on risk for patients between 40 and
65 years and requires separate input for each individual
using charts or an online calculator, which was not prac-
tical in our large cohort. To verify that the Framingham
risk score was applicable in our cohort, we calculated the
PC-based HeartScore for 50 randomly selected incident
RA cases and 50 controls. Parallel Framingham risk scores
and HeartScores were used to calculate an equation per-
mitting estimation of the HeartScore in the entire cohort
from their Framingham risk scores. An alternative logistic
model was developed substituting the Framingham risk
score with these estimated HeartScores. In addition,
we compared factors associated with incident cases of
self-reported RA with incident cases of self-reported
osteoarthritis.
Results
The baseline characteristics of the participants are pre-
sented in Table 1. At baseline (1995 to 1997) 33,567 par-
ticipants reported not having RA, and of this group 786
(2.34%) reported RA at follow-up (2006 to 2008). This
corresponds to an average annual incidence of 0.21% in
women and 0.16% in men, respectively. If restricted to
participants with cases identified in the local hospital
registries (n = 216), the annual incidence was 0.06% in
women and 0.04% in men. As expected, incident cases
of RA were older and more of them were current or pre-
vious smokers and had hypertension at baseline. Inci-
dent cases of RA had significantly elevated metabolic
risk factors including blood pressure, BMI, serum chol-
esterol and triglyceride. The estimated median (inter-
quartile range) Framingham risk scores at baseline were
11 (7, 16) and 8 (4, 13), respectively, in incident cases
and those who did not develop RA. Notably, a higher
proportion of incident RA cases had a history of CV dis-
ease at baseline.
Female gender, age, smoking, BMI and previous CV
disease were more prominent in those developing RA
(odds ratio 1.52 (1.11 to 2.07), Table 2, I - Main model).
There was minimal change in the odds ratio for previous
CV disease with inclusion of use of analgesics in this lo-
gistic regression model, when systolic and diastolic
blood pressure were included as continuous variables in-
stead of the categorical variable for hypertension, with
additional adjustment for total cholesterol and HDL-
cholesterol concentrations, or when a variable for phys-
ical activity (low, moderate, high) was also included (data
not shown). In all the alternative multivariate models for
incident RA where the number of patients was restricted
to better characterized subgroups, previous CV disease
was significant and the odds ratios were higher than for
the main model including all self-reported cases (Table 2,












n 33,567 786 32,781 3,586 29,981
Age1 (years) 46 (13) 51 (13) 46 (13) ** 52 (10) 45 (13) **
Sex (female) 18,207 (54.2%) 488 (62.1%) 17719 (54.1%) ** 2,406 (67.1%) 15,801(52.7%) **
Smoking ** **
Current 8,901 (26.5%) 256 (32.6%) 8,645 (26.4%) 1,015 (28.3%) 7,886 (26.3%)
Former smoker 7,908 (23.6%) 212 (27.0%) 7,696 (23.5%) 945 (26.4%) 6,963 (23.2%)
Never smoker 15,017 (44.7%) 281 (35.6%) 14,736 (45.0%) 1,425 (39.7%) 13,592 (45.3%)
Hypertension 12,186 (36.3%) 339 (43.1%) 11,847 (36.1%) ** 1,547 (43.1%) 10,639 (35.5%) **
Diabetes 454 (1.4%) 19 (2.4%) 435 (1.3%) * 61 (1.7%) 393 (1.3%)
Previous CV disease 1,060 (3.2%) 52 (6.6%) 1,008 (3.1%) ** 158 (4.4%) 902 (3.0%) **
Angina 673 (2.0%) 35 (4.5%) 638 (1.9%) ** 107 (3.0%) 566 (1.9%) **
MI 441 (1.3%) 16 (2.0%) 425(1.3%) 49 (1.4%) 392 (1.3%)
Stroke 223 (0.7%) 9 (1.1%) 214 (0.7%) 32 (0.9%) 191 (0.6%)
Family risk of CV disease 15,692 (46.7%) 414 (52.7%) 15,278 (46.6%) ** 2,017 (56.2%) 13,675 (45.6%) **
Framingham risk score2 9 (4 to 13) 11 (7 to 16) 8 (4 to 13) 11 (7 to 15) 8 (3 to 13)
Weight1 (kg) 76 (14) 77 (14) 76 (14) 77 (13) 76 (14)
BMI2 (kg/m2) 25.6 (23.5 to 28.1) 26.3 (24.3 to 29.0) 25.6 (23.4 to 28.1) ** 26.4 (24.2 to 29.0) 25.4 (23.3 to 27.8) **
Waist circumference1 (cm) 85 (11) 86 (11) 85 (11) * 86 (11) 85 (11) **
Hip circumference1 (cm) 102 (8) 103 (8) 102 (8) ** 103 (8) 101 (6) **
Waist/hip ratio1 0.84 (0.08) 0.84 (0.08) 0.84 (0.08) 0.83 (0.07) 0.84 (0.08) **
Systolic blood pressure2
(mmHg)
131 (120 to 144) 133 (122 to 146) 131 (120 to 144) * 133 (122 to 147) 131 (120 to 143) **
Diastolic blood pressure1
(mmHg)
79 (11) 80 (11) 79 (11) * 81 (11) 79 (11) **
Serum cholesterol1 (mmol/L) 5.8 (1.2) 6.0 (1.2) 5.8 (1.2) ** 6.1 (1.2) 5.8 (1.2) **
HDL cholesterol1 (mmol/L) 1.40 (0.39) 1.37 (0.39) 1.40 (0.39) 1.44 (0.40) 1.39 (0.38) **
Serum triglycerides2 (mmol/L) 1.40 (0.98 to 2.07) 1.51 (1.10 to 2.24) 1.40 (0.97 to 2.06) ** 1.46 (1.02 to 2.12) 1.37 (0.95 to 2.04) **
1Values are mean (standard deviation) or numbers (%), or 2median (interquartile range). Non-respondents were excluded. BMI, body mass index; CVD, cardiovascular
disease; HDL, high density lipoprotein; MI, myocardial infarction; OA, osteoarthritis; RA, rheumatoid arthritis. *P-value <0.05, **P-value <0.001, comparing individuals who
developed RA and did not develop RA, or comparing individuals who developed OA and did not develop OA. All blood samples were non-fasting.
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confirmed in the hospital registries for 216 participants
(27%) who had self-reported a new RA diagnosis in
HUNT3. The characteristics of these participants were
very similar to those reported for the entire group of in-
cident RA cases (data not shown). In the 216 cases with
a hospital diagnosis of RA, the diagnosis was found one
to two years following enrolment in HUNT2 for 14
cases (6.5%), after three years for 24 cases (11.1%), after
four years for 15 cases (6.9%), after five years for 28
cases (13.0%) and after six years for 22 cases (10.2%). For
the remaining 113 cases (52.3%), the times were distributed
from seven years onwards to the inclusion in HUNT3 with
numbers varying unsystematically from 15 to 24 cases
(6.9 to 11.1%) per year. Thus, there was no obvious pat-
tern regarding the number of years from HUNT2.In a separate alternative multivariate logistic regression
model containing gender, previous CV disease and the
Framingham risk score as covariates, the odds ratio for
developing RA in subjects with previous CV disease was
1.65 (1.21 to 2.24) (P <0.01). This model also suggested
the likelihood of developing RA was 6% greater with
each one unit increase in Framingham risk score (odds
ratio: 1.06, 95% CI: 1.05 to 1.08), P <0.001). The model
did not change with adjustment for BMI or daily use of
over-the-counter analgesics. In the model where the
Framingham risk score was substituted with the estimated
HeartScore, previous cardiovascular disease remained
significant (odds ratio: 1.70 (1.25 to 2.32), P <0.01). In the
100 participants where the HeartScore was calculated using
the PC-based calculator, the HeartScore (logarithmically
transformed) was highly correlated with the Framingham
Table 2 Effects of risk factors on incident RA and osteoarthritis, by multivariate logistic regression
Odds ratio 95% confidence interval P-value
I - Main model – Rheumatoid arthritis (n = 739 patients and 30,829 controls)1
Female gender 1.50 1.29 to 1.75 <0.01
Age2 1.03 1.02 to 1.04 <0.001
Current smoker 1.64 1.38 to 1.96 <0.001
Former smoker 1.32 1.10 to 1.59 <0.01
Hypertension 0.97 0.82 to 1.15 0.76
Diabetes 1.34 0.83 to 2.18 0.23
Body mass index2 1.04 1.02 to 1.06 <0.001
Previous CV disease 1.52 1.11 to 2.07 <0.01
II - Alternative models (sensitivity analyses) - Rheumatoid arthritis
A – After exclusion of patients with self-reported psoriasis (n = 573 patients and 30,829 controls)1
Previous CV disease3 1.70 1.23 to 2.36 0.001
B – Including patients with hospital diagnosis of RA (n = 201 patients and 30,829 controls)1
Previous CV disease3 1.90 1.10 to 3.27 0.02
C – Including patients with hospital diagnosis of RA after 1999 (n = 178 patients and 30,829 controls)1
Previous CV disease3 2.26 1.26 to 3.99
D – Including patients with hospital diagnosis of RA after 2001 (n = 138 patients and 30,829 controls)1
Previous CV disease3 2.51 1.33 to 4.73 <0.01
E – Including patients carrying the Shared Epitope (n = 313 patients and 30,829 controls)1
Previous CV disease3 1.76 1.13 to 2.74 0.01
F – Including patients carrying the Shared Epitope and excluding patients with self-reported psoriasis (n = 257 patients and 30,829 controls)1
Previous CV disease3 1.96 1.24 to 3.10 <0.01
III - Model for osteoarthritis (n = 3,364 patients and 24,631 controls)1
Female gender 2.36 2.15 to 2.56 <0.001
Age2 1.05 1.05 to 1.06 <0.001
Current smoker 1.42 1.30 to 1.56 <0.001
Former smoker 1.23 1.12 to 1.35 <0.001
Diabetes 0.90 0.66 to 1.22 0.49
Body mass index2 1.06 1.05 to 1.07 <0.001
Previous CV disease 1.04 0.86 to 1.27 0.66
1Cases with complete data.
2Continuous variable, Odds ratio per one unit change.
3Multivariate model including the same variables as the main model for RA. CV, cardiovascular; RA, rheumatoid arthritis.
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similar in patients (R = 0.89) and controls (R = 0.86).
At follow-up (2006 to 2008), 3,586 participants had
developed osteoarthritis, corresponding to an average
annual incidence of 1.05% in women and 0.64% in men,
respectively. These patients were older and the propor-
tion of smokers, former smokers and of those with
hypertension was higher than in the group that did not
develop osteoarthritis. Systolic and diastolic blood pres-
sure, BMI, hip and waist circumference, total cholesterol
and triglycerides were higher for incident cases of osteo-
arthritis, whereas HDL cholesterol was lower in incident
cases of osteoarthritis. Female gender, age and smokingwere associated with development of osteoarthritis, whereas
previous CV disease was not (Table 2 III).
Discussion
In the present large population-based health study we
found that participants who developed RA between
HUNT2 and HUNT3 had more CV disease and CV risk
factors prior to the onset of RA (at HUNT2) compared
to those without incident RA. A history of CV disease
was a significant risk factor for incident RA, as well as
the previously reported risk factors: female gender, in-
creasing age, increasing BMI and smoking [25]. The
finding of a positive association with the Framingham
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corporated into the score. The supplementary analysis
showed that the Framingham score was equivalent to the
estimated HeartScore in our population even though the
Framingham score was not developed from European sub-
jects. On the other hand, previous CV disease events did
not contribute to the risk of future osteoarthritis in our
study, indicating that the finding may be specific to RA.
Smoking was associated with incident osteoarthritis.
CV disease and incident RA
The design of our study has several strengths. Since the
data on the CV risk factors and events were collected at
HUNT2, recall bias at HUNT3 was greatly reduced com-
pared to a design where patients report on these factors
when receiving an RA diagnosis at a hospital-based clinic.
Furthermore, the observation time between HUNT2 and
HUNT3 was approximately 10 years. The importance of a
long observation time is underscored by the finding that
the odds ratio for the association of incident RA with pre-
vious CV disease increased when patients receiving a hos-
pital diagnosis of RA during the first years following
HUNT2 were excluded. It also seems biologically plausible
that longer exposure to increased inflammation due to CV
disease further increases the risk of incident RA. Further-
more, the statistical power is greatly improved in a
population-based cohort study due to the large number of
controls, and problems defining a relevant control group
as seen with case-control studies of RA are avoided.
The major limitation of our study is that data were
self-reported. Previous studies suggest that self-reported
CV diagnosis and risk factors, such as hypertension and
cigarette smoking, are reliable [26,27]. However, the high
incidence rate of self-reported RA in our study com-
pared, for example, to recent Swedish data based on in-
patient and non-primary outpatient care (0.056% in
women, 0.025% in men) [28], confirms that there prob-
ably were many false-positive RA diagnoses. This would
tend to decrease the power to detect true positive results
in our study, but not bias towards false-positive findings.
When including only cases identified in the hospital
registries, the incidence was close to the Swedish data.
Furthermore, the incidence of RA increases with obser-
vation time [29]. Therefore, different data may not be
directly comparable.
Epidemiological studies also carry a risk of reverse
causation, which could ensue if persons with undiag-
nosed RA in HUNT2 were erroneously included as inci-
dent cases of RA, because RA in itself increases the risk
of CV disease and events [10]. It seems unlikely that re-
verse causation could explain our findings, given that
the association with previous CV disease became stron-
ger when the cases with shortest duration between
HUNT2 and a hospital diagnosis of RA were removedfrom the analysis. Furthermore, we did not observe a
tendency for a higher number of cases with a hospital
diagnosis to occur during the earliest years following
HUNT2, which would have been expected with substan-
tial reverse causation.
While fatal CV events prior to the onset of RA also lim-
ited the participants in our study to survivors of those
events, this again would lead to under-estimation of the
impact of CV events on development of RA, or to restrict
the population at risk of RA to those ageing with CV risk
that was insufficient to lead to premature mortality. Auto-
antibodies were not measured and seropositive and sero-
negative cases of RA could not be distinguished, which
impacts on the generalizability of our results compared to
others, such as population-based cohorts where it was
concluded that ischemic heart disease was not increased
prior to RA onset [17]. There may also have been a selec-
tion bias regarding participation in HUNT, where sicker
people or those with a lower socioeconomic status are less
likely to join. These people have a higher risk both for CV
disease and for RA, which may have biased our findings.
The results from our various sensitivity analyses unani-
mously supported our main analysis. The overall conclu-
sion that a history of CV disease is associated with the risk
for incident RA therefore seems reliable. Although our
study may not be suitable to give an exact estimate of the
size of this increased risk, the main analysis giving an OR
of approximately 1.5 is probably conservative.
Risk factors for osteoarthritis
Our results identifying smoking as a risk factor for fu-
ture osteoarthritis contradict some previous studies,
which report an inverse association between smoking
and osteoarthritis [30]. However, the longitudinal pro-
spective Clearwater study designed to identify risk factors
for OA development, which included 2,505 participants,
did not support this inverse association with smoking for
any of four joint sites (knee, hand, foot or spine) [31].
In another prospective study of 1,003 participants from
the general population there was no association between
smoking and radiologically-confirmed OA at different
sites [32]. The current study may have shown an asso-
ciation with smoking because it is larger and included
a greater number of incident osteoarthritis diagnoses.
Nevertheless, since our study relies on self-report, replica-
tion in a cohort ascertained for radiographic osteoarthritis
and symptoms is needed. However, in support of the ac-
curacy of our case classification, we noted that higher BMI
increased the risk for osteoarthritis development, as previ-
ously described [33].
Inflammation as a link between CV disease and incident RA
From a biological perspective based on the current stud-
ies, we hypothesize that inflammation may contribute to
Figure 1 Proposed model for illustrating the relationship
among RA, CV disease, inflammation, atherosclerosis and
predisposing factors. CV, cardiovascular; RA, rheumatoid arthritis.
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ing the pre-clinical period in individuals exposed to
common RA and CV risk factors, just as this interaction
accelerates complication of RA by CV events after onset.
Inflammation is the most plausible link between previous
CV disease or BMI and increased risk for RA. It is well
established that the pathogenesis of CV disease, that is,
atherogenesis, includes chronic inflammation of the wall of
muscular arteries and that inflammation is increased during
acute coronary events, associated with unstable plaque and
thrombosis [16]. Furthermore, obesity induces chronic in-
flammation in adipose tissue, increasing pro-inflammatory
cytokines including interleukin-6 and tumour-necrosis
factor [34]. In addition, a pro-inflammatory state is present
before the clinical onset of RA. C reactive protein (CRP)
levels were found to be higher in individuals with pre-
clinical RA compared to a control group [35]. Serum cyto-
kines and chemokines were also elevated preceding the
onset of RA [36]. In at least some patients, periodontal in-
flammation may precede the onset of RA symptoms, also
associated with ACPA [37]. Respiratory inflammation has
also been described in ACPA positive individuals without
RA [38]. Autoantibodies may also increase the risk of im-
mune complex-mediated vascular inflammation [39]. Thus,
CV disease and CV risk factors increase the future risk of
RA development in the context of systemic inflammation
and autoantibody development [12]. Patients with seroposi-
tive RA are at greater risk of CV disease [6,40], and it is
possible that the RA genetic background is more permis-
sive to atherosclerosis when associated with the “lifestyle”
factors described here. In contrast to RA, in osteoarthritis
inflammation is local and low-grade rather than systemic,
and is not associated with autoantibodies.
Figure 1 proposes a model for the relationships among
RA, CV disease, inflammation and various predisposing
factors, based on the results from the present study, aswell as previous studies demonstrating an increased risk
of CV disease after diagnosis of RA. Given that our find-
ings were robust when adjusting for known risk factors
for RA, this hypothesis merits further investigation in
studies designed to clarify pathogenetic mechanisms,
which is not possible in an epidemiological study.
Conclusions
A history of previous CV disease was associated with in-
creased risk of incident RA but not osteoarthritis. A
probable explanation is that increased systemic inflam-
mation may contribute to the parallel development of
atherosclerosis and RA during the pre-clinical period in
individuals exposed to common RA and CV risk factors,
in a similar way that such interaction accelerates CV dis-
ease in patients with established RA. The association of
previous CV events with the development of RA at the
population level suggests presentation with CV events,
especially in middle-aged female smokers or first-degree
relatives of RA patients, should raise clinical suspicion
to capture cases of undiagnosed early RA. Because CV
risk factors are increased at the onset of RA, active car-
diovascular risk management is important from the time
of diagnosis.
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